Lieping Chen

94.7k total citations · 26 hit papers
368 papers, 55.6k citations indexed

About

Lieping Chen is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Lieping Chen has authored 368 papers receiving a total of 55.6k indexed citations (citations by other indexed papers that have themselves been cited), including 296 papers in Immunology, 181 papers in Oncology and 35 papers in Molecular Biology. Recurrent topics in Lieping Chen's work include Immunotherapy and Immune Responses (209 papers), Immune Cell Function and Interaction (158 papers) and Cancer Immunotherapy and Biomarkers (139 papers). Lieping Chen is often cited by papers focused on Immunotherapy and Immune Responses (209 papers), Immune Cell Function and Interaction (158 papers) and Cancer Immunotherapy and Biomarkers (139 papers). Lieping Chen collaborates with scholars based in United States, China and Germany. Lieping Chen's co-authors include Dallas B. Flies, Koji Tamada, Gefeng Zhu, Weiping Zou, Haidong Dong, Miguel F. Sanmamed, Drew M. Pardoll, Xue Han, Jedd D. Wolchok and Scott E. Strome and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Lieping Chen

361 papers receiving 54.9k citations

Hit Papers

Tumor-associated B7-H1 promotes T-cell apoptosis: A poten... 1992 2026 2003 2014 2002 2010 2013 1999 2014 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
    2002 4.0k citations Haidong Dong, Scott E. Strome et al. profile →
  2. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
    2010 2.3k citations Julie R. Brahmer, Charles G. Drake et al. profile →
  3. Molecular mechanisms of T cell co-stimulation and co-inhibition
    2013 2.3k citations Lieping Chen, Dallas B. Flies profile →
  4. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
    1999 2.1k citations Haidong Dong, Gefeng Zhu et al. profile →
  5. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
    2014 1.9k citations Janis M. Taube, Alison Klein et al. Clinical Cancer Research profile →
  6. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
    2016 1.9k citations Weiping Zou, Lieping Chen et al. profile →
  7. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
    2012 1.7k citations Janis M. Taube, Robert A. Anders et al. profile →
  8. Inhibitory B7-family molecules in the tumour microenvironment
    2008 1.3k citations Weiping Zou, Lieping Chen profile →
  9. Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
    2015 1.1k citations Lieping Chen et al. profile →
  10. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
    2018 1.1k citations Miguel F. Sanmamed, Lieping Chen Cell profile →
  11. Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
    2004 1.0k citations Lieping Chen profile →
  12. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
    1992 912 citations Lieping Chen et al. Cell profile →
  13. B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
    2001 828 citations Julie S. Lau, Dallas B. Flies et al. profile →
  14. Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity
    2005 794 citations Fumiya Hirano, Katsumi Kaneko et al. Cancer Research profile →
  15. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
    1997 727 citations Ignacio Melero, Lieping Chen et al. profile →
  16. Programmed death ligand-1 expression in non-small cell lung cancer
    2013 652 citations Vamsidhar Velcheti, Kurt A. Schalper et al. profile →
  17. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
    2004 635 citations R. Houston Thompson, Michael D. Gillett et al. Proceedings of the National Academy of Sciences profile →
  18. Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
    2013 602 citations Sofía Lyford-Pike, Shiwen Peng et al. Cancer Research profile →
  19. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
    2006 581 citations Ilona Kryczek, Gefeng Zhu et al. profile →
  20. B7-H4, a Molecule of the B7 Family, Negatively Regulates T Cell Immunity
    2003 568 citations Gefeng Zhu, Koji Tamada et al. profile →
  21. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells
    2010 534 citations Lieping Chen et al. profile →
  22. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
    2019 488 citations Jun Wang, Dallas B. Flies et al. profile →
  23. Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
    2019 470 citations Deborah B. Doroshow, Miguel F. Sanmamed et al. Clinical Cancer Research profile →
  24. Resistance Mechanisms to Anti-PD Cancer Immunotherapy
    2022 281 citations Lieping Chen et al. profile →
  25. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
    2022 244 citations Roy S. Herbst, Lieping Chen et al. profile →
  26. Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
    2025 21 citations María Villalba, Miguel F. Sanmamed et al. Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lieping Chen United States 112 36.0k 34.3k 9.2k 6.6k 3.4k 368 55.6k
Suzanne L. Topalian United States 82 27.0k 0.7× 32.6k 1.0× 12.4k 1.3× 7.7k 1.2× 2.3k 0.7× 215 49.2k
Jedd D. Wolchok United States 119 29.7k 0.8× 45.3k 1.3× 16.2k 1.8× 11.0k 1.7× 3.3k 1.0× 568 65.0k
F. Stephen Hodi United States 101 16.7k 0.5× 34.2k 1.0× 10.4k 1.1× 9.8k 1.5× 2.6k 0.8× 517 44.0k
Arlene H. Sharpe United States 130 47.7k 1.3× 28.8k 0.8× 16.3k 1.8× 4.6k 0.7× 5.9k 1.8× 408 75.8k
Mark J. Smyth Australia 143 52.9k 1.5× 37.6k 1.1× 20.2k 2.2× 5.1k 0.8× 5.5k 1.6× 595 81.6k
John M. Kirkwood United States 104 18.8k 0.5× 31.3k 0.9× 17.9k 1.9× 4.4k 0.7× 4.8k 1.4× 687 46.4k
Dmitry I. Gabrilovich United States 97 41.6k 1.2× 25.8k 0.8× 15.6k 1.7× 4.3k 0.7× 2.4k 0.7× 266 57.3k
Gordon J. Freeman United States 141 54.1k 1.5× 38.6k 1.1× 14.7k 1.6× 8.3k 1.3× 6.8k 2.0× 419 82.7k
Wolf H. Fridman France 100 31.2k 0.9× 27.6k 0.8× 16.6k 1.8× 8.5k 1.3× 2.6k 0.8× 529 57.4k
Yang‐Xin Fu United States 99 22.5k 0.6× 14.2k 0.4× 9.8k 1.1× 3.5k 0.5× 3.0k 0.9× 377 37.9k

Countries citing papers authored by Lieping Chen

Since Specialization
Citations

This map shows the geographic impact of Lieping Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lieping Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lieping Chen more than expected).

Fields of papers citing papers by Lieping Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lieping Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lieping Chen. The network helps show where Lieping Chen may publish in the future.

Co-authorship network of co-authors of Lieping Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Lieping Chen. A scholar is included among the top collaborators of Lieping Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lieping Chen. Lieping Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Villalba, María, et al.. (2025). Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach. Nature Reviews Clinical Oncology. 22(3). 163–181. 21 indexed citations breakdown →
2.
Nassar, Ala F., Xinxin Nie, Jacky T. Yeung, et al.. (2024). Is Lipid Metabolism of Value in Cancer Research and Treatment? Part II: Role of Specialized Pro-Resolving Mediators in Inflammation, Infections, and Cancer. Metabolites. 14(6). 314–314. 8 indexed citations
3.
Zhao, Yu, Lieping Chen, & Genshan Ma. (2023). Cardiac fibroblasts-mtExosomes-macrophages axis aggravates ventricular remodeling after acute myocardial infarction. European Heart Journal. 44(Supplement_2). 2 indexed citations
4.
Melero, Ignacio, Miguel F. Sanmamed, Javier Glez‐Vaz, et al.. (2022). CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary. Cancer Discovery. 13(3). 552–569. 51 indexed citations
5.
Doroshow, Deborah B., Miguel F. Sanmamed, Katherine Hastings, et al.. (2019). Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes. Clinical Cancer Research. 25(15). 4592–4602. 470 indexed citations breakdown →
6.
Sanmamed, Miguel F. & Lieping Chen. (2018). A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 175(2). 313–326. 1110 indexed citations breakdown →
7.
Villarroel‐Espíndola, Franz, Xiaoqing Yu, Ila Datar, et al.. (2017). Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer. Clinical Cancer Research. 24(7). 1562–1573. 162 indexed citations
8.
Kluger, Harriet M., Christopher R. Zito, Gabriela Turcu, et al.. (2017). PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research. 23(15). 4270–4279. 111 indexed citations
9.
Jacquelot, Nicolas, David Enot, Sylvie Rusakiewicz, et al.. (2016). Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. Journal of Investigative Dermatology. 136(5). 994–1001. 22 indexed citations
10.
Schalper, Kurt A., Daniel Carvajal‐Hausdorf, Joseph McLaughlin, et al.. (2016). Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. Clinical Cancer Research. 23(2). 370–378. 160 indexed citations
11.
Weigelin, Bettina, Elixabet Bolaños, Álvaro Teijeira, et al.. (2015). Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Proceedings of the National Academy of Sciences. 112(24). 7551–7556. 81 indexed citations
12.
Kluger, Harriet M., Christopher R. Zito, Meaghan L. Barr, et al.. (2015). Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clinical Cancer Research. 21(13). 3052–3060. 163 indexed citations
13.
Taube, Janis M., Alison Klein, Julie R. Brahmer, et al.. (2014). Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy. Clinical Cancer Research. 20(19). 5064–5074. 1873 indexed citations breakdown →
14.
Lyford-Pike, Sofía, Shiwen Peng, Geoffrey D. Young, et al.. (2013). Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma. Cancer Research. 73(6). 1733–1741. 602 indexed citations breakdown →
15.
Park, Jang‐June, Ryusuke Omiya, Yumiko Matsumura, et al.. (2010). B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood. 116(8). 1291–1298. 266 indexed citations
16.
Wu, Ke, Ilona Kryczek, Lieping Chen, Weiping Zou, & Theodore H. Welling. (2009). Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions. Cancer Research. 69(20). 8067–8075. 313 indexed citations
17.
Zhu, Gefeng, Mathew M. Augustine, Takeshi Azuma, et al.. (2008). B7-H4–deficient mice display augmented neutrophil-mediated innate immunity. Blood. 113(8). 1759–1767. 68 indexed citations
18.
Tirapu, Iñigo, Eduardo Huarte, Cristiana Guiducci, et al.. (2006). Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma. Cancer Research. 66(4). 2442–2450. 116 indexed citations
19.
Hirano, Fumiya, Katsumi Kaneko, Hideto Tamura, et al.. (2005). Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity. Cancer Research. 65(3). 1089–1096. 794 indexed citations breakdown →
20.
Thompson, R. Houston, Michael D. Gillett, John C. Cheville, et al.. (2004). Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proceedings of the National Academy of Sciences. 101(49). 17174–17179. 635 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Suzanne L. Topalian Breakdown of academic impact, for papers by Jedd D. Wolchok Breakdown of academic impact, for papers by F. Stephen Hodi Breakdown of academic impact, for papers by Arlene H. Sharpe Breakdown of academic impact, for papers by Mark J. Smyth Breakdown of academic impact, for papers by John M. Kirkwood Breakdown of academic impact, for papers by Dmitry I. Gabrilovich Breakdown of academic impact, for papers by Gordon J. Freeman Breakdown of academic impact, for papers by Wolf H. Fridman Breakdown of academic impact, for papers by Yang‐Xin Fu
Rankless by CCL
2026